A Pilot Study of Bladder Preservation or Cystectomy for Muscle-invasive Bladder Cancer Guided by Multi-omics: the B-PRECISE Study
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Feasibility Failure Rate (FFR)
研究概览
简要总结
In this research study, investigators will assess whether it is feasible to use information from the genes of a tumor combined with evaluation of the tumor response to systemic therapy to determine if bladder sparing chemoradiation can be used or if surgery to remove the bladder, or radical cystectomy, is needed.
详细描述
This is a single-center, early phase 1 pilot study in which investigators will assess whether it is feasible to use information from the genes of a tumor combined with evaluation of the tumor response to systemic therapy to determine if bladder sparing chemoradiation can be used or if surgery to remove the bladder, or radical cystectomy, is needed.
Perioperative systemic therapy with surgical removal of the bladder or chemoradiation are standard treatments for muscle-invasive bladder cancer. The investigational part of this study is using specific information from the tumor and response to therapy to guide a standard-of-care treatment decision.
The research study procedures include screening for eligibility, standard of care systemic therapy, cystoscopy with biopsy, Magnetic Resonance Imaging studies, either bladder sparing chemoradiation or surgical removal of the bladder, blood tests, urine tests, questionnaires, and follow up visits.
Participation in this research study is expected to last for 2 years.
It is expected about 20 people will take part in this research study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have signed written informed consent indicating understanding of the purpose of the study and willingness to participate prior to any protocol-related procedures, including screening evaluation.
- •Participants must have histologically confirmed cT2-cT4aN0M0 urothelial (transitional cell) carcinoma of the bladder. Mixed histology is acceptable as long as there is a majority component of urothelial carcinoma.
- •Availability of baseline archival tumor tissue obtained for molecular analysis and correlative studies
- •Age ≥ 18 years
- •Candidate for radical cystectomy
- •Cisplatin eligible
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Participants infected with human immunodeficiency virus on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- •Participants with evidence of chronic hepatitis B virus infection with an undetectable HBV viral load on suppressive therapy, if indicated, are eligible for this trial
- •Participants with a history of hepatitis C virus (HCV) must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- •Participants with a prior or concurrent history of malignancy whose natural history of treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational protocol are eligible for this trial
- •Participants must have adequate organ and marrow function as defined below:
- •Leukocytes ≥3,000/mcL
- •Hemoglobin ≥9.0 g/dL
- •Absolute neutrophil count ≥1,500/mcL
- •Platelets ≥100,000/mcL
- •International Normalized ratio ≤1.5 x institutional upper limit of normal (ULN) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN
- •Unless the patient is receiving anticoagulation therapy provided INR or PTT is within the therapeutic range of the intended anticoagulant
- •Total bilirubin ≤ institutional upper limit of normal (ULN)
- •This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed in consultation with their physician
- •AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN
- •Measured creatinine clearance ≥ 50 mL/min or calculated creatinine clearance 50mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:
- •Males: Creatinine CL (mL/min) = Weight (kg) x (140 - Age) 72 x serum creatinine (mg/dL)
- •Females: Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)
- •Evidence of post-menopausal status or negative urinary or serum pregnancy test for pre-menopausal female patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
- •Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- •Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of treatment.
- •Patient is willing and able to comply with the protocol for the duration of the trial
排除标准
- •Patients with urothelial carcinoma of the ureter, urethra, or renal pelvis
- •Contraindication for bladder radiation
- •Inoperable primary tumor
- •Any previous systemic chemotherapy or radiotherapy for bladder cancer
- •Inflammatory bowel disease
- •Patients who are receiving or have received any other investigational agents within 6 months of study entry
- •Child-Pugh class C hepatic impairment
- •Receipt of the last dose of intravesical chemotherapy or biologic therapy ≤ 42 days (6 weeks) prior to the first dose of study drug for patients who have received prior intravesical chemotherapy or biologic therapy (e.g. BCG)
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, unstable cardiac arrhythmia, symptomatic interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
- •Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements
- •Pregnant women are excluded from this study because chemotherapy and radiation have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy, breastfeeding should be discontinued if the mother is treated with chemotherapy.
研究组 & 干预措施
Arm A: Chemoradiation Therapy
Participants who are 1) molecular positive after standard of care neoadjuvant therapy and have a clinical complete response, OR 2) molecular negative after standard of care neoadjuvant therapy and have a clinical complete response with ≤cT1 disease can opt for chemoradiation therapy and will complete:
-
Chemoradiation therapy of either:
-
Predetermined dose of Cisplatin 1x weekly
-
Predetermined dose of Gemcitabine 2x weekly
-
Predetermined dose of 5FU continuous infusion for days 1-5 and 16-20 in combination with predetermined dose of Mitomycin 1x on day 1
-
Predetermined dose of Cisplatin and 5FU 1x daily on days 1-3, 8-10, 15-17 for the duration of radiation.
-
Radiation regimen per investigator discretion for 4 or 7 weeks.
-
CT chest and CT or MRI of abdomen and pelvis.
-
Follow Up Period Visits: CT chest and CT or MRI of abdomen and pelvis and cystoscopy with possible biopsy or removal of residual cancer tissue.
-
End of study visit.
干预措施: Adrucil (Drug)
Arm B: Radical Cystectomy
Participants who have cT2 disease after standard of care neoadjuvant therapy will undergo standard of care RC and will complete:
- Radical cystectomy
- CT chest and CT or MRI of abdomen and pelvis.
- Follow Up Period Visits: CT chest and CT or MRI of abdomen and pelvis and cystoscopy with possible biopsy or removal of residual cancer tissue.
- Participants are eligible to receive standard of care adjuvant therapy
- End of study visit.
干预措施: Radical Cystectomy (Procedure)
Arm A: Chemoradiation Therapy
Participants who are 1) molecular positive after standard of care neoadjuvant therapy and have a clinical complete response, OR 2) molecular negative after standard of care neoadjuvant therapy and have a clinical complete response with ≤cT1 disease can opt for chemoradiation therapy and will complete:
-
Chemoradiation therapy of either:
-
Predetermined dose of Cisplatin 1x weekly
-
Predetermined dose of Gemcitabine 2x weekly
-
Predetermined dose of 5FU continuous infusion for days 1-5 and 16-20 in combination with predetermined dose of Mitomycin 1x on day 1
-
Predetermined dose of Cisplatin and 5FU 1x daily on days 1-3, 8-10, 15-17 for the duration of radiation.
-
Radiation regimen per investigator discretion for 4 or 7 weeks.
-
CT chest and CT or MRI of abdomen and pelvis.
-
Follow Up Period Visits: CT chest and CT or MRI of abdomen and pelvis and cystoscopy with possible biopsy or removal of residual cancer tissue.
-
End of study visit.
干预措施: Mitomycin (Drug)
Arm A: Chemoradiation Therapy
Participants who are 1) molecular positive after standard of care neoadjuvant therapy and have a clinical complete response, OR 2) molecular negative after standard of care neoadjuvant therapy and have a clinical complete response with ≤cT1 disease can opt for chemoradiation therapy and will complete:
-
Chemoradiation therapy of either:
-
Predetermined dose of Cisplatin 1x weekly
-
Predetermined dose of Gemcitabine 2x weekly
-
Predetermined dose of 5FU continuous infusion for days 1-5 and 16-20 in combination with predetermined dose of Mitomycin 1x on day 1
-
Predetermined dose of Cisplatin and 5FU 1x daily on days 1-3, 8-10, 15-17 for the duration of radiation.
-
Radiation regimen per investigator discretion for 4 or 7 weeks.
-
CT chest and CT or MRI of abdomen and pelvis.
-
Follow Up Period Visits: CT chest and CT or MRI of abdomen and pelvis and cystoscopy with possible biopsy or removal of residual cancer tissue.
-
End of study visit.
干预措施: Cisplatin (Drug)
Arm A: Chemoradiation Therapy
Participants who are 1) molecular positive after standard of care neoadjuvant therapy and have a clinical complete response, OR 2) molecular negative after standard of care neoadjuvant therapy and have a clinical complete response with ≤cT1 disease can opt for chemoradiation therapy and will complete:
-
Chemoradiation therapy of either:
-
Predetermined dose of Cisplatin 1x weekly
-
Predetermined dose of Gemcitabine 2x weekly
-
Predetermined dose of 5FU continuous infusion for days 1-5 and 16-20 in combination with predetermined dose of Mitomycin 1x on day 1
-
Predetermined dose of Cisplatin and 5FU 1x daily on days 1-3, 8-10, 15-17 for the duration of radiation.
-
Radiation regimen per investigator discretion for 4 or 7 weeks.
-
CT chest and CT or MRI of abdomen and pelvis.
-
Follow Up Period Visits: CT chest and CT or MRI of abdomen and pelvis and cystoscopy with possible biopsy or removal of residual cancer tissue.
-
End of study visit.
干预措施: Gemzar (Drug)
结局指标
主要结局
Feasibility Failure Rate (FFR)
时间窗: Approximately 16 weeks after initiation of neoadjuvant chemotherapy
FFR defined as the proportion of participants that achieve feasibility failure. Feasibility is defined as the ability to derive interpretable information from ≥70% of evaluable patients from tumor genomics and/or transcriptomic studies before NAC plus mpMRI or cystoscopic evaluation and urine cytology to guide the patient toward an informed decision for bladder preservation chemoradiation vs. RC. Evaluable patients are those who initiate planned NAC.
次要结局
- Clinical Complete Response (cCR) Rate(Approximately 16 weeks after initiation of neoadjuvant chemotherapy)
- Bladder Preserving Rate(Approximately 24 weeks after initiation of neoadjuvant chemotherapy, at time of definitive therapy)
- Median Bladder-Intact Disease-Free Survival (BIDFS)(Disease evaluated radiolagically after completion of cisplatin-based neoadjuvant chemotherapy and after definitive treatment with chemoradiation/radical cystectomy.In long-term follow-up,data collected every 3-6 months for 2 years or progressive disease.)
- Recurrence Rate at 1 Year(Relevant to this endpoint is at 1 year)
- Recurrence Rate at 2 Year(Relevant to this endpoint is at 2 year)
- 1-Year Overall Survival (OS)(In long-term follow-up, participants were assessed every 6 months, up to 2 years. Relevant to this endpoint is the estimate at 1 year.)
- 2-year Overall Survival (OS)(In long-term follow-up, participants were assessed every 6 months, up to 2 years. Relevant to this endpoint is the estimate at 2 years.)
- Longitudinal assessment of quality of life using the Bladder Cancer Index(Data are collected baseline, after neoadjuvant chemotherapy, after definitive treatment (CRT/RC), during follow-up and off sutdy visit, with up to 2 years of follow up.)
研究者
Charlene Mantia
Principle Investigator
Dana-Farber Cancer Institute